Key Highlights
- Lilly became the first pharmaceutical company to be valued above 1 trillion dollars, with shares tripling since early 2023.
- Zepbound generated 4.9 billion dollars in sales in its first full year, with 2026 sales expected to reach roughly four times that figure.
- Lilly has committed more than 50 billion dollars to expanding manufacturing capacity since 2020.
- The company paid 7.8 billion dollars in June to acquire Centessa Pharmaceuticals, a narcolepsy treatment developer.
A Historic Valuation Built on Obesity Drug Dominance
Eli Lilly (NYSE:LLY) has become the world's most valuable drugmaker and the first pharmaceutical company to surpass a trillion dollars in market value, joining a club largely dominated by technology giants. Since the start of 2023, its share price has more than tripled, with analysts expecting revenue to grow around 15% annually on average through the end of the decade, more than three times the median growth rate of its peers, leading investors to value Lilly more like a technology company than a traditional drugmaker.
Much of this optimism rests on GLP-1 obesity drugs, a category that has transformed both Lilly and the broader pharmaceutical industry. Zepbound, Lilly's weight-loss treatment, generated 4.9 billion dollars in sales during its first full year on the market in 2024, with analysts expecting 2026 sales to reach roughly four times that figure. The company now accounts for three-fifths of GLP-1 sales in America, and Bloomberg Intelligence estimates Lilly could capture two-thirds of a global obesity-drug market worth more than 120 billion dollars annually by 2030.
A More Ambitious Vision Beyond Obesity
Lilly Chief Executive Dave Ricks has outlined a broader ambition beyond dominating the obesity drug market alone, aiming to transform the company into one focused on keeping people healthy rather than simply treating disease, while borrowing business ideas from Silicon Valley. Lilly's rapid rise in obesity drugs helps explain this confidence: despite Danish rival Novo Nordisk launching its treatment more than two years earlier in America, Zepbound had overtaken Novo's drug by 2025, a result Ricks attributes to both superior science, including greater weight loss with fewer side effects, and stronger execution through early manufacturing investment and quicker recognition that obesity would become a consumer market as much as a medical one.
With more than 120 companies now developing competing obesity drugs and at least 190 candidates in clinical trials, Lilly's strategy involves covering the chessboard with treatments offering different combinations of efficacy, tolerability and convenience, while leaning on its manufacturing scale as a key competitive advantage, having committed more than 50 billion dollars to expanding production capacity since 2020.
Pursuing Prevention Rather Than Treatment Alone
Beyond weight loss, GLP-1 drugs have shown benefits in reducing the risk of cardiovascular disease, sleep apnoea and chronic kidney disease, with early evidence suggesting potential applications for addiction and psychiatric illness. This has led Lilly to pursue a bigger question: whether its medicines can prevent diseases from developing in the first place, a focus shaping the company's broader drug pipeline.
In June, Lilly paid 7.8 billion dollars to acquire Centessa Pharmaceuticals, a biotech company developing a treatment for narcolepsy, a condition affecting the brain's ability to regulate sleep cycles. Lilly's chief scientist noted that part of the appeal of sleep-regulating drugs lies in the possibility that their benefits could prove as broad as those seen with GLP-1s. The company is also testing its Alzheimer's drug, donanemab, in patients without symptoms to determine whether early treatment can delay or even prevent the disease from developing.
Borrowing a Technology Company Playbook, With Caveats
Ricks acknowledges the preventive care model comes with significant challenges, noting that today's healthcare systems are designed to treat illness rather than prevent it, and that the immediate costs of preventive medicines against savings that may not materialise for years make them difficult for insurers to value and reimburse. Prevention also risks over-diagnosis and over-treatment, raising difficult questions about who should receive medicines and when.
Building a prevention-focused business requires staying closer to patients than pharma has traditionally done, prompting Ricks to increasingly describe Lilly less as a drugmaker and more as a technology company, emphasising frictionless customer experience and platform-based approaches. LillyDirect, the company's online pharmacy, represents one attempt to build a more direct relationship with consumers, with more than half of new patients starting Lilly's GLP-1 treatments now coming through online channels including LillyDirect. Ricks also frames GLP-1s not simply as a product but as a platform, a common foundation on which multiple medicines can be built by adding other hormones, with manufacturing crossovers allowing other injectable drugs to share much of the same production network and helping lower costs.
A Measured View on Artificial Intelligence's Near-Term Role
Ricks warns against what he calls enshittification, the tendency of platforms to serve themselves rather than their users, describing it as a risk healthcare cannot afford. He also expresses more caution than some industry figures about artificial intelligence's near-term potential in drug discovery. While Lilly has partnered with Nvidia to build what the companies describe as the industry's most powerful AI supercomputer for training biomedical models, and has begun sharing AI models trained on proprietary data with selected biotech companies in exchange for reciprocal data sharing, Ricks cautions that today's AI models do not understand biology and that their role in drug discovery will remain limited until they can reason about the underlying rules of the body, describing the path ahead as a long and difficult ride. He argues the nearer-term gains from AI are more likely to come from simplifying the broader healthcare system's administrative burden rather than accelerating drug discovery itself.
Conclusion
Eli Lilly's ambitions extend well beyond maintaining its current dominance in the obesity drug market, reflecting a broader bet that preventive medicine, platform-based drug development and a more direct consumer relationship can reshape how the pharmaceutical industry operates. Whether this Silicon Valley-inspired approach can successfully navigate the structural challenges of a healthcare system built around treating rather than preventing illness, particularly around reimbursement and over-treatment risk, may determine whether Lilly's broader reinvention proves as transformative as its rise in obesity medicine has already been.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...